Simultaneous detection of CYP3A5 and MDR1 polymorphisms based on the SNaPshot assay

被引:8
|
作者
Li, Liang [2 ]
Li, Chuan-Jiang [1 ]
Zhang, Yan-Jun [3 ]
Zheng, Lei
Jiang, Hai-Xia
Si-Tu, Bo
机构
[1] So Med Univ, Nanfang Hosp, Dept Organ Transplantat, Guangzhou 510515, Guangdong, Peoples R China
[2] So Med Univ, Sch Basic Med Sci, Guangzhou 510515, Guangdong, Peoples R China
[3] Univ Cincinnati, Coll Pharm, Acad Hlth Ctr, Cincinnati, OH 45267 USA
关键词
CYP3A5; MDR1; SNP; Genotyping; Sequencing; SINGLE-NUCLEOTIDE POLYMORPHISMS; P-GLYCOPROTEIN; GENETIC POLYMORPHISMS; PHARMACOKINETICS; DISPOSITION; C3435T; PCR; GENOTYPES; G2677T/A; C1236T;
D O I
10.1016/j.clinbiochem.2010.12.018
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: The 6986A > G polymorphism for CYP3A5 and the -129T > C, 1236C > T, 2677G > T/A, and 3435C > T polymorphisms for MDR1 are considered the major genetic factors affecting a range of drugs' metabolism and transport. Simultaneous genotyping of these five polymorphisms would be useful for estimating the therapeutic effects of their related drugs. Subjects and methods: We have described a SNaPshot assay that can simultaneously detect all the five polymorphisms based on multiplex PCR and minisequencing reaction. A total of 168 unrelated Chinese DNA samples were used to establish and evaluate the assay. Results: The different genotypes of the five polymorphisms could be determined by peak retention time and colors. DNA sequencing was performed on samples randomly selected from each of the genotype groups detected by SNaPshot assay, and the results indicated 100% concordance. Conclusion: The SNaPshot assay for the CYP3A5 and MDR1 five polymorphisms detection was accurate, automated, and cost-effective. (C) 2011 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:418 / 422
页数:5
相关论文
共 50 条
  • [1] CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation
    Anglicheau, D
    Thervet, E
    Etienne, I
    De Ligny, BH
    Le Meur, Y
    Touchard, G
    Büchler, M
    Laurent-Puig, P
    Tregouet, D
    Beaune, P
    Daly, A
    Legendre, C
    Marquet, P
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (05) : 422 - 433
  • [2] Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups
    Li, D.
    Zhang, G-L.
    Lou, Y-Q.
    Li, Q.
    Wang, X.
    Bu, X-Y.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2007, 32 (01) : 89 - 95
  • [3] INFLUENCE OF CYP3A5, CYP2C19 AND MDR1 GENETIC POLYMORPHISMS ON THE PHARMACOKINETICS OF CILOSTAZOL
    Kim, Se-Mi
    Park, Sun-Ae
    Kang, Hyun-Ah
    Cho, Hea-Young
    Shin, Sae-Byeok
    Lee, Yong-Bok
    [J]. DRUG METABOLISM REVIEWS, 2008, 40 : 151 - 151
  • [4] Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects
    Choi, Ji H.
    Lee, Yoon J.
    Jang, Seong B.
    Lee, Jong-Eun
    Kim, Kyung H.
    Park, Kyungsoo
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 64 (02) : 185 - 191
  • [5] CYP3A5 and MDR1 polymorphisms in pediatric kidney transplant recipients receiving calcineurin inhibitors
    Tirelli, Amedea Silvia
    Ghio, Luciana
    Ferraresso, Mariano
    Belingheri, Mirco
    Berardinelli, Luisa
    Turolo, Stefano
    Torresani, Erminio
    Edefonti, Alberto
    [J]. THERAPEUTIC DRUG MONITORING, 2007, 29 (04) : 544 - 544
  • [6] Impact of CYP3A5 and MDR1 polymorphisms on tacrolimus and sirolimus kinetics of kidney transplant recipients
    Frisman, M
    Renders, L
    Haenisch, S
    Mosyagin, I
    Cascorbi, I
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (09) : 705 - 706
  • [7] Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation
    Zhang, X
    Liu, ZH
    Zheng, JM
    Chen, ZH
    Tang, Z
    Chen, JS
    Li, LS
    [J]. CLINICAL TRANSPLANTATION, 2005, 19 (05) : 638 - 643
  • [8] Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation
    Hu, Yong-Fang
    Qiu, Wen
    Liu, Zhao-Qian
    Zhu, Li-Jun
    Liu, Zhong-Qi
    Tu, Jiang-Hua
    Wang, Dan
    Li, Zhi
    He, Jun
    Zhong, Gan-Ping
    Zhou, Gan
    Zhou, Hong-Hao
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2006, 33 (11) : 1093 - 1098
  • [9] Investigation of Quetiapine Pharmacokinetics and its Correlation With CYP3A5 or MDR1 Polymorphisms: A Population Pharmacokinetic Approach
    Shilbayeh, Sireen
    Melhem
    Zmeili, Rawan
    [J]. THERAPEUTIC DRUG MONITORING, 2013, 35 (05) : 715 - 715
  • [10] Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms
    Zheng, HX
    Webber, S
    Zeevi, A
    Schuetz, E
    Zhang, J
    Bowman, P
    Boyle, G
    Law, Y
    Miller, S
    Lamba, J
    Burckart, GJ
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (04) : 477 - 483